This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Baldwin GC, Tashkin DP, Buckley DM, Park AN, Dubinett SM, Roth MD (1997) Habitual smoking of marijuana and cocaine impairs alveolar macrophage function and cytokine production. J Resp Crit Care Med 156: 1606–1613
Beal JA (1994) Appetite effect of dronabinol. J Clin Oncol 12: 1524–1525
Campbell FA, Tramèr MR Carroll D, Reynolds DJ, Moore RA, McQuay HJ (2001) Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative and systematic review. BMJ 323: 13–16
Jatoi A, Windschitl HE, Loprinzi CL, Sloan JA, Dakhil SR, Mailliard JA, Pundaleeka S, Kardinal CG, Fitch TR, Krook JE, Novotny PJ, Chistensen B (2002) Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study. J Clin Oncol 20: 567–573
Kalso E (2001) Cannabinoids for pain and nausea. BMJ 323: 2–3
Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, DiMarzo V, Lutz B (2002) The endogenous cannabinoid system controls extinction of aversive memories. Nature 418: 530–534
Mechoulam R, Hanu L (2001) The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 6: 67–73
Radbruch L, Nauck F (2004) Cannabinoide in der Behandlung von übelkeit und Erbrechen. Schmerz 18: 306–310
Reynolds R (2002) Comparative efficacy of dronabinol and megestrol acetate. J Clin Oncol 20: 2912–2913
Smith PF (2002) Cannabinoids in the treatment of pain and spasticity in multiple sclerosis. Curr Opin Investig Drugs 3: 859–864
Svendsen KB, Jensen TS, Bach FW (2004) Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? BMJ 329: 257–258
Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD (2002) Respiratory and immunologic consequences of marijuana smoking. J Clin Pharmacol 42: 71–81
Timpone JG, Wright DJ, Li N, Egorin MJ, Enama ME, Mayers J, Galetto G (1997) The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the tratment of HIV wasting syndrome. Aids Res Human Retroviruses 13: 305–315
Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ (2001) Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ 323: 16–21
Walker JM, Huang SM (2002) Cannabinoid analgesia. Phamacol Ther 95: 127–135
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A (2003) Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 362: 1517–1526
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer-Verlag/Wien
About this chapter
Cite this chapter
Kress, H.G., Kraft, B. (2006). Cannabinoide in der Palliativmedizin. In: Schmerzbehandlung in der Palliativmedizin. Springer, Vienna. https://doi.org/10.1007/3-211-32188-8_13
Download citation
DOI: https://doi.org/10.1007/3-211-32188-8_13
Publisher Name: Springer, Vienna
Print ISBN: 978-3-211-25289-5
Online ISBN: 978-3-211-32188-1
eBook Packages: Medicine (German Language)